User menu

Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome

  2. Sandler Robert S., Epidemiology of irritable bowel syndrome in the United States, 10.1016/0016-5085(90)91023-y
  3. Talley Nicholas J., Zinsmeister Alan R., van Dyke Carol, Melton L.Joseph, Epidemiology of colonic symptoms and the irritable bowel syndrome, 10.1016/0016-5085(91)90717-y
  4. Drossman Douglas A., Li Zhiming, Andruzzi Eileen, Temple Robert D., Talley Nicholas J., Grant Thompson W., Whitehead William E., Janssens Josef, Funch-Jensen Peter, Corazziari Enrico, Richter Joel E., Koch Gary G., U. S. Householder survey of functional gastrointestinal disorders : Prevalence, sociodemography, and health impact, 10.1007/bf01303162
  5. Farthing MJG, Q J Med, 88, 451 (1995)
  6. Hungin A. P. S., Whorwell P. J., Tack J., Mearin F., The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects, 10.1046/j.1365-2036.2003.01456.x
  7. Thompson WG, Gastroenterol Int, 5, 75 (1992)
  8. Camilleri Michael, The Irritable Bowel Syndrome: Mechanisms and a Practical Approach to Management, 10.7326/0003-4819-116-12-1001
  9. Zighelboim Jaime, Talley Nicholas J., What are functional bowel disorders?, 10.1016/0016-5085(93)90293-l
  10. Lynn Richard B., Friedman Lawrence S., Irritable Bowel Syndrome, 10.1056/nejm199312233292608
  11. Whitehead WE, Dig Dis Sci, 295, 557 (1982)
  12. Drossman DA, Gut, 45, II25 (1999)
  13. Drossman Douglas A., The Irritable Bowel Syndrome: Review and a Graduated Multicomponent Treatment Approach, 10.7326/0003-4819-116-12-1009
  14. Crowell MD, Am J Manag Care, 7, S252 (2001)
  15. Farthing Michael J.G., New Drugs in the Management of the Irritable Bowel Syndrome : , 10.2165/00003495-199856010-00002
  16. Kuipers E.J., Review article: exploring the link between Helicobacter pylori and gastric cancer, 10.1046/j.1365-2036.1999.00002.x
  17. Talley N. J., Phillips S. F., Haddad A., Miller L. J., Twomey C., Zinsmeister A. R., MacCarty R. L., Ciociola A., GR 38032F (Ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man, 10.1007/bf01536922
  18. Camilleri, Mayer, Drossman, Heath, Dukes, Mcsorley, Kong, Mangel, Northcutt, Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist, 10.1046/j.1365-2036.1999.00610.x
  19. Delvaux M., Louvel D., Mamet J.-P., Campos-Oriola R., Frexinos J., Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome, 10.1046/j.1365-2036.1998.00375.x
  20. Delvaux M, Gastroenterol Clin Biol, 25, C42 (2001)
  21. Cremonini F., Delgado-Aros S., Camilleri M., Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials, 10.1046/j.1365-2982.2003.00389.x
  22. Evans BW, Cochrane Database Syst Rev, CD003960 (2004)
  23. Patel Sonal, Berrada Driss, Lembo Anthony, Review of tegaserod in the treatment of irritable bowel syndrome, 10.1517/14656566.5.11.2369
  24. Muller-Lissner S. A., Fumagalli I., Bardhan K. D., Pace F., Pecher E., Nault B., Ruegg P., Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation, 10.1046/j.1365-2036.2001.01094.x
  25. Scott Lesley J., Perry Caroline M., Tegaserod : , 10.2165/00003495-199958030-00013
  26. Dumuis Aline, Sebben Michèle, Bockaert Joël, BRL 24924: a potent agonist at a non-classical 5-HT receptor positively coupled with adenylate cyclase in colliculi neurons, 10.1016/0014-2999(89)90304-x
  27. Briejer MR, Pharmacol Rev, 47, 631 (1995)
  28. CAMILLERI M, MCKINZIE S, FOX J, FOXXORENSTEIN A, BURTON D, THOMFORDE G, BAXTER K, ZINSMEISTER A, Effect of renzapride on transit in constipation-predominant irritable bowel syndrome, 10.1016/s1542-3565(04)00391-x
  29. George A, Gut, 52, SVI (2003)
  30. Meyers NL, Gut, 51, SIII (2002)
  31. Meyers NL, Gut, 51, SIII (2002)
  32. Peroutka SJ, TINS, 11, 496 (1988)
  33. Stanniforth DH, Eur J Clin Pharmacol, 38, 161 (1990)
  34. Krevsky B, Aliment Pharmacol Ther, 1, 293 (1987)
  35. Ghevens J, Letter - Propulsid Tablets and Suspension (Cisapride)
  36. Ferriman A., UK licence for cisapride suspended, 10.1136/bmj.321.7256.259
  37. Tonini, De Ponti, Di Nucci, Crema, Review article: cardiac adverse effects of gastrointestinal prokinetics, 10.1046/j.1365-2036.1999.00655.x
  38. Farrington E, Pediatr Nurs, 22, 256 (1996)
  39. Manning AP, Br Med J, 2, 653 (1978)
  40. Thomson WG, Gastroenterol Int, 5, 75 (1992)
  41. Abrahamsson H, Scand J Gastroenterol, 23, 72 (1988)
  42. Mackie AD, Aliment Pharmacol Ther, 2, 135 (1991)
  43. Kellow J, An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome, 10.1136/gut.52.5.671
  44. Berardi Rosemary R., Safety and Tolerability of Tegaserod in Irritable Bowel Syndrome Management, 10.1331/154434504322713228
Bibliographic reference Tack, Jean-Pierre ; Piessevaux, Hubert ; Middleton, SJ ; Horne, MC ; Bloor, JS ; et. al. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome. In: Alimentary Pharmacology and Therapeutics, Vol. 23, no. 11, p. 1655-65 (2006)
Permanent URL